Role of Uremic Toxins in Mild Cognitive Impairment in Chronic Kidney Disease (MOMENTUM)
Investigator-initiated, Multicentre, International, Cross-sectional and Longitudinal Clinical Study Elucidating the Pathophysiology of Mild Cognitive Impairment in Chronic Kidney Disease With a Focus on the Role of Uremic Toxins
MOMENTUM is an investigator-initiated, multicentre, international, controlled, cross-sectional and longitudinal clinical study, which aims to evaluate the association between plasma levels of UTs and the presence and severity of cognitive impairment, and their mechanistic interplay in study participants with CKD at different disease stages.
The study consists of three main phases: a screening period, a cross-sectional (baseline) phase, and an 18-month follow-up (longitudinal phase).
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
- Behaviorální: MoCA Test
- Diagnostický test: Laboratory tests
- Diagnostický test: Non-contrast-enhanced brain MRI
- Behaviorální: Comprehensive neuropsychological test battery
- Behaviorální: Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, first section
- Behaviorální: Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, other sections
- Behaviorální: Questionnaires
- Behaviorální: New MCI-CKD QoL Questionnaire
Detailní popis
Chronic kidney disease (CKD) represents a major and growing global health challenge, affecting over 800 million people worldwide across stages. Its prevalence is increasing due to rising rates of diabetes, hypertension, and obesity, the most common causes of CKD, and the disease is projected to become the fifth leading cause of death by 2040. CKD has been recently prioritized within the WHO noncommunicable diseases agenda in alignment with the United Nation's Sustainable Development Goal (SDG) 3.4 and 3.8. Beyond its direct contribution to morbidity and mortality and its established role as a major risk factor for cardiovascular disease, CKD also significantly impacts neurological health.
Cognitive impairment - particularly Mild Cognitive Impairment (MCI) - is increasingly recognized as a frequent but underexplored complication, occurring at more than twice the rate observed in age-matched individuals from the general population. MCI markedly increases the risk of progression to dementia, and is associated with substantial consequences for patients, caregivers, healthcare systems, and society, highlighting the importance of early identification and intervention.
Despite its clinical and societal importance, MCI-CKD remains an under-recognized health challenge. Its pathophysiological mechanisms are poorly understood, no specific biomarkers have been validated to support diagnosis or prognosis, and no established guidelines exist for its systematic monitoring or management. Most patients remain unaware of the condition, and healthcare providers often overlook it. This lack of awareness and diagnostic capacity hampers timely interventions, including referrals for symptomatic treatments, cognitive rehabilitation strategies, or preventive measures.
As a transitional stage preceding clinical dementia, early identification of MCI-CKD may allow nephrologists to refer patients to neurologists for symptomatic treatments and cognitive rehabilitation strategies.18 Patients diagnosed with MCI-CKD may also be referred for other interventions addressing other modifiable drivers of MCI, such as sleep, stress, dietary habits, exercise and cardiovascular disease.
Clinically, CKD is characterized by a progressive decline in kidney function, typically assessed by the glomerular filtration rate (GFR), which can be estimated through equations based on serum creatinine, cystatin C, or a combination of both (eGFR), or directly measured using exogenous filtration markers such as iohexol or iothalamate clearance (mGFR). Additional indicators of kidney damage include blood urea nitrogen (BUN) levels, the urinary albumin-to-creatinine ratio (ACR), and histological findings from kidney biopsy. However, accurately quantifying nephron loss and the extent of renal fibrosis remains challenging. As kidney function declines, disturbances develop in electrolyte, water, acid-base, and mineral homeostasis. Uremic toxins (UTs) accumulate, and renal anaemia emerges. Several CKD-related factors, including metabolic alterations, inflammation, vascular dysfunction, and UT accumulation, have been independently associated with an increased risk of cognitive impairment.
The MOMENTUM cross-sectional and longitudinal clinical study is designed to address this critical gap. By comprehensively characterizing cognitive impairment in CKD and integrating multimodal biomarkers, including circulating and microbiome-derived uremic toxins, advanced neuroimaging, and clinical assessments, it aims to improve early detection and risk stratification of MCI-CKD. This knowledge will contribute to a better understanding of disease mechanisms, support earlier diagnosis, and enable the development of targeted strategies to reduce cognitive decline and dementia burden in individuals with CKD.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Matias Trillini, M.D.
- Telefonní číslo: +390354535411
- E-mail: matias.trillini@marionegri.it
Studijní místa
-
-
-
Naples, Itálie, 80131
- AOU University of Campania "Luigi Vanvitelli"
-
Kontakt:
- Alessandra Perna
- Telefonní číslo: +390815666822
- E-mail: alessandra.perna@unicampania.it
-
-
BG
-
Ranica, BG, Itálie, 24020
- Clinical Research Centre for Rare Diseases Aldo e Cele Daccò
-
Kontakt:
- Matias Trillini, M.D.
- Telefonní číslo: +390354535411
- E-mail: matias.trillini@marionegri.it
-
-
-
-
-
Derby, Spojené království, DE22 3NE
- University Hospitals of Derby and Burton NHS Foundation Trust
-
Kontakt:
- Nicholas Selby
- Telefonní číslo: +44(0)1332724665
- E-mail: nicholas.selby@nottingham.ac.uk
-
-
-
-
-
Pamplona, Španělsko, 31008
- Clínica Universidad de Navarra
-
Kontakt:
- Nuria Garcia Fernandez, MD PhD
- Telefonní číslo: +34948255400
- E-mail: nrgarcia@unav.es
-
-
-
-
-
Lausanne, Švýcarsko, 1005
- Centre Hospitalier Universitaire Vaudois
-
Kontakt:
- Menno Pruijm, Prof.
- Telefonní číslo: +41(0)213141131
- E-mail: Menno.Pruijm@chuv.ch
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria
- Male or female aged 40-75 years at time of screening;
- Availability for longitudinal follow-up;
- Signed informed consent
Specifically for CKD participants:
- CKD stage G3a/G3b, or stage G4-G5 without kidney replacement therapy, or stage G5 undergoing hemodialysis (HD) for more than 3 months;
- MoCA score in the range [18-25];41
Specifically for controls:
-
Normal renal function:
- For controls aged < 65 years, eGFR ≥ 90 mL/min/1.73 m2;
- For controls aged ≥ 65 years, eGFR ≥ 60 mL/min/1.73 m2.
-
No detectable proteinuria at screening (negative urine dipstick);
-
MoCA score ≥ 26/30.
Exclusion Criteria
- Contraindication to MRI including claustrophobia, pregnancy or breastfeeding, cardiac pacemakers, aneurysm clips, or other MRI-incompatible devices, or inability to undergo MRI;
- Pre-existing neurological disorders known to affect cognitive function (e.g., dementia, Parkinson's disease, multiple sclerosis, epilepsy or neurodegenerative disorders);
- History of ischemic or hemorrhagic stroke and/or previous brain surgery;
- History of severe traumatic brain injury;
- Treated or untreated clinically significant depressive disorder that, in the investigator's judgment, may interfere with cognitive assessment;
- Recent hospitalization for acute events within the last 3 months, except for percutaneous transluminal angioplasty (PTA) of fistula, catheter replacement and elective hospitalizations;
- Serious acute illness within the last 3 months;
- Active solid tumors with or without metastasis;
- Inflammatory bowel disease;
- Systemic corticosteroid treatment for > 6 months at a prednisone-equivalent dose > 10 mg/day;
- Planned pregnancy during the 18-month follow-up period;
Specifically for CKD patients:
- Peritoneal dialysis;
- Kidney transplantation at enrolment;
Specifically for controls:
● Any chronic clinically significant condition, except for hypertension treated with < 3 antihypertensive drugs.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Jiný
- Přidělení: Nerandomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Group 1
Patients with CKD stage G3 (eGFR 30-59 mL/min/1.73 m2), balanced between the two sub-stages G3a (eGFR 45-59 mL/min/1.73 m2) and G3b (eGFR 30-44 mL/min/1.73 m2) |
Montreal Cognitive Assessment Test The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI) The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)] "Your Health" section, corresponding to the SF-12 questionnaire Sections specific to kidney disease excluding the first section Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq). Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively. Frailty will be evaluated using the Clinical Frailty Scale (CFS). The new MCI-CKD-specific quality of life questionnaire developed within the MOMENTUM project |
|
Experimentální: Group 2
Patients with CKD stages G4-G5 without kidney replacement therapy (eGFR < 30 mL/min/1.73 m2) |
Montreal Cognitive Assessment Test The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI) The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)] "Your Health" section, corresponding to the SF-12 questionnaire Sections specific to kidney disease excluding the first section Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq). Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively. Frailty will be evaluated using the Clinical Frailty Scale (CFS). The new MCI-CKD-specific quality of life questionnaire developed within the MOMENTUM project |
|
Experimentální: Group 3
Patients with CKD stage G5 on chronic hemodialysis (eGFR < 15 mL/min/1.73 m2) |
Montreal Cognitive Assessment Test The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI) The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)] "Your Health" section, corresponding to the SF-12 questionnaire Sections specific to kidney disease excluding the first section Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq). Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively. Frailty will be evaluated using the Clinical Frailty Scale (CFS). The new MCI-CKD-specific quality of life questionnaire developed within the MOMENTUM project |
|
Experimentální: Group 4
Healthy controls |
Montreal Cognitive Assessment Test The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI) The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)] "Your Health" section, corresponding to the SF-12 questionnaire Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq). Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively. Frailty will be evaluated using the Clinical Frailty Scale (CFS). |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Correlation between blood levels of the 6 predefined UTs (individually and in combination) and the presence and severity of cognitive impairment, within each CKD group separately.
Časové okno: Baseline (Visit 2, Day 0)
|
Correlation coefficient (e.g., Pearson's r or Spearman's rho). The coefficient is computed for each of the 6 UTs and for the combination, within each CKD group separately. |
Baseline (Visit 2, Day 0)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: Norberto Perico, M.D., Istituto Di Ricerche Farmacologiche Mario Negri
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Urogenitální onemocnění
- Duševní poruchy
- Patologické procesy
- Mužská urogenitální onemocnění
- Onemocnění ledvin
- Urologická onemocnění
- Ženské urogenitální onemocnění
- Ženské urogenitální onemocnění a těhotenské komplikace
- Chronické onemocnění
- Atributy nemoci
- Neurokognitivní poruchy
- Poruchy kognice
- Renální insuficience
- Patologické stavy, příznaky a symptomy
- Kognitivní dysfunkce
- Renální insuficience, chronická
- Kvalita zdravotní péče, přístup a hodnocení
- Vyšetřovací techniky
- Epidemiologické metody
- Diagnostické techniky a postupy
- Diagnóza
- Sběr dat
- Mechanismy hodnocení zdravotní péče
- Kvalita zdravotní péče
- Veřejné zdraví
- Životní prostředí a veřejné zdraví
- Průzkumy a dotazníky
- Klinické laboratorní techniky
Další identifikační čísla studie
Další identifikační čísla studie
- MOMENTUM
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .